Small cars have several advantages for consumers. First among these is fuel efficiency. Second is that most small cars cost less than larger ones. These may be more than offset by the fact that small vehicles often are not safe to drive. Although the problem makes sense, it was driven home by recent research. And the research results may undermine sales in the important segment, robbing the industry of momentum.
The Insurance Institute for Highway Safety (IIHS) announced:
Only 1 minicar out of 11 tested achieves an acceptable rating in the Insurance Institute for Highway Safety’s small overlap front crash test, making these tiny vehicles the worst performing group of any evaluated so far.
General Motors Co.’s (NYSE: GM) Chevrolet Spark made the cut. The Honda Motor Co. Ltd. (NYSE: HMC) Fit, Toyota Motor Corp. (NYSE: TM) Yaris and Prius C, Ford Motor Co. (NYSE: F) Fiesta, Kia Rio, Hyundai Accent, Fiat 500, Mazda 2, Mitsubishi Mirage and Nissan Versa sedan did not.
Best High Tech Companies To Buy For 2015: Red Robin Gourmet Burgers Inc.(RRGB)
Red Robin Gourmet Burgers, Inc., together with its subsidiaries, develops, operates, and franchises casual-dining restaurants in the United States and Canada. As of February 16, 2012, the company operated 465 Red Robin restaurants, including 328 company-owned restaurants and 137 restaurants operating under franchise agreements. Its restaurants offer gourmet burgers, as well as various salads, soups, appetizers, entrees, desserts, and signature Mad Mixology alcoholic and non-alcoholic specialty beverages Red Robin Gourmet Burgers, Inc. was founded in 1969 and is headquartered in Greenwood Village, Colorado.
Advisors' Opinion:- [By Ben Levisohn]
Shares of Cracker Barrel have gained 0.9% to $113.29 and�Biglari Holdings (BH), Sandar Biglari’s holding company, has fallen 0.4% to $516.96, on a day when DineEquity has advanced 1% to $85.03, Red Robin Gourmet Burgers (RRGB) has risen 0.5% to $76.64 and Denny’s (DENN) is up 0.7% at $7.45.
- [By Lisa Levin]
Red Robin Gourmet Burgers (NASDAQ: RRGB) shares climbed 3.04% to $54.23. The volume of Red Robin shares traded was 398% higher than normal. On Thursday, Red Robin reported downbeat second-quarter profit.
- [By Damian Illia]
Burger fans probably know Red Robin Gourmet Burgers Inc. (RRGB). Founded in Seattle, Red Robin Gourmet Burgers is a full-service casual dining restaurant chain that operates franchises and develops restaurants under the name of Red Robin Gourmet Burgers. By October 2013, Red Robin operated 350 company-owned restaurants and 135 franchised restaurants across the US and Canada. This burger-loving firm not only serves a broad variety of burgers made from beef, chicken, fish, pork and turkey, as well as veggie patties, but also offers salads, sandwiches, soups, entrees and the famous all-you-can-eat steak fries. Furthermore, a limited service non-traditional prototype restaurant is being developed by the company, named Red Robin�� Burger Works.
- [By Jayson Derrick]
Analysts at Jefferies maintained a Buy rating on Red Robin Gourmet Burger (NYSE: RRGB) with a price target lowered to $80 from a previous $90. Also, analysts at Wunderlich maintained a Buy rating on Red Robin with a price target raised to $92 from a previous $76. Shares gained 4.31 percent, closing at $54.90.
10 Best Performing Stocks To Own For 2014: NewLead Holdings Ltd.(NEWL)
NewLead Holdings Ltd. operates as an international shipping company that owns and operates product tankers and dry bulk carriers. It operates in two segments, Wet Operations and Dry Operations. The Wet Operations segment transports various refined petroleum products simultaneously in segregated coated cargo tanks that include gasoline, jet fuel, kerosene, naphtha, and gas oil. The Dry Operations segment involves in transporting and handling bulk cargoes through ownership, operation, and trading of vessels. As of August 2, 2011, the company operated a fleet of 6 double-hull product tankers and 16 dry bulk vessels. The company was formerly known as Aries Maritime Transport Limited and changed its name to NewLead Holdings Ltd. in December 2009. NewLead Holdings Ltd. was incorporated in 2005 and is based in Athens, Greece.
Advisors' Opinion:- [By James E. Brumley]
Back in early November, yours truly penned some bullish thoughts on FreeSeas Inc. (NASDAQ:FREE), NewLead Holdings Ltd (NASDAQ:NEWL), and DryShips Inc. (NASDAQ:DRYS). While each stock has its own merits, the crux of the bullishness was ultimately rooted in the brewing rebound of the Baltic Dry Index... a reflection of the prices companies pay shippers like FreeSeas and DryShips to haul goods over the ocean.
- [By Bryan Murphy]
The last few weeks have been, shall we say "interesting" for maritime shipping stocks like FreeSeas Inc. (NASDAQ:FREE), DryShips Inc. (NASDAQ:DRYS), and NewLead Holdings Ltd (NASDAQ:NEWL). The strong rise in the Baltic Dry Index - the average daily charter rate of a dry goods vessel - since mid-August (and really since early June) has meant maritime shippers can charge more for their services, and who knows? Maybe they can even turn a profit sometime in the foreseeable future. As a result of that possibility, DRYS gained nearly 100% in a little over a month., NEWL was up as much as 70% at one point in late September, and FREE advanced nearly 300% on the heels of the Baltic Dry Index's runup from 1000 to more than 2000 in just a little over a month.
10 Best Performing Stocks To Own For 2014: Medina International Holdings Inc (MIHI)
Medina International Holdings, Inc. (Medina), incorporated on June 23, 1998, manufactures products and services to assist emergency and defense organizations and personnel. The Company, through its two wholly owned subsidiaries, Harbor Guard Boats, Inc. (HGB) and Medina Marine, Inc. manufactures and sells recreational and commercial boats. The products are manufactured by HGB, which designs, manufactures, and markets hand-laid fiberglass and aluminum commercial boats ranging from 15 feet to 37 feet, which are utilized by fire, search and rescue, emergency, patrol, military and defense organizations. It manufactures commercial and recreational watercrafts.
As of April 30, 2012, HGB had nine models of commercial and recreational watercrafts. The Company�� products consist of commercial boats and recreational boats. As of April 30, 2012, Medina had seven commercial watercraft models, ranging from 15 feet to 37 feet in length. Its other watercraft includes 15 feet interceptor, which is used for rescue and fiber glass; 20-feet interceptor, which is used for fire rescue, rescue and fiber glass; 21 feet firecat, which is used for fire rescue, rescue and fiber glass; 24 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 26 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass; 30 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass, and 37 feet firecat/denfender, which is used for fire rescue, rescue, aluminum and fiber glass. As of April 30, 2012, the Company had two recreational watercraft models. Its watercraft products are made out of fiberglass and aluminum materials.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap Digital Brand Media & Marketing Group Inc (OTCMKTS: DBMM) surged 22.22% while Blue Water Global Group Inc (OTCBB: BLUU) sank 18.42% and Medina International Holdings, Inc (OTCMKTS: MIHI) sank 50%. However, one of these small caps (Blue Water Global Group) appears to be reversing course in early morning trading today. So with it and the rest of these small cap stocks either sink or swim in trading this week? Here is a closer look to help you decide on an investing or trading strategy:
10 Best Performing Stocks To Own For 2014: Celgene Corp (CELG)
Celgene Corporation is a global biopharmaceutical company primarily engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. The Company is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. The Company�� primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.
The Company invests in research and development, and the drug candidates in its pipeline at various stages of preclinical and clinical development. These candidates include pomalidomide and apremilast, its oral anti-cancer and anti-inflammatory agents, PDA-001, its cellular therapy, oral azacitidine, CC-223 and CC-115 for hematological and solid tumor malignancies, CC-122, its anti-cancer pleiotropic pathway modifier, and ACE-011 and ACE-536 biological products for anemia in several clinical settings of unmet need. Celgene product candidates include Pomalidomide (CC-4047), Oral Anti-Inflammatory: Apremilast (CC-10004), CC-11050, Kinase Inhibitors:Tanzisertib (CC-930), Cellular Therapies: PDA-001, Activin Biology: Sotatercept (ACE-011) ACE-536, and Anti-tumor Agents: CC-22, CC-115, CC-122 and Oral Azacitidine. It owns and operates a manufacturing facility in Zofingen, Switzerland. The Company also owns and operates a drug product manufacturing facility in Boudry, Switzerland.
Commercial! Stage Products
REVLIMID (lenalidomide) is an oral immunomodulatory drug marketed in the United States and many international markets, in combination with dexamethasone, for treatment of patients with multiple myeloma who have received at least one prior therapy. It is also marketed in the United States and certain international markets for the treatment of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. REVLIMID is distributed in the United States through contracted pharmacies under the RevAssist program, which is a risk-management distribution program. Internationally, REVLIMID is distributed under mandatory risk-management distribution programs.
REVLIMID continues to be evaluated in numerous clinical trials worldwide either alone or in combination with one or more other therapies in the treatment of a range of hematological malignancies, including multiple myeloma (MDS) various lymphomas, chronic lymphocytic leukemia (CLL) other cancers and other diseases. VIDAZA (azacitidine for injection) is a pyrimidine nucleoside. VIDAZA is a Category 1 recommended treatment for patients with intermediate-2 and high-risk MDS and is marketed in the United States for the treatment of all subtypes of MDS. In Europe, VIDAZA is marketed for the treatment of intermediate-2 and high-risk MDS, as well as acute myeloid leukemia (AML) with 30% blasts and has been granted orphan drug designation for the treatment of MDS and AML.
THALOMID (thalidomide) is marketed for patients with newly diagnosed multiple myeloma and for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) an inflammatory complication of leprosy and as maintenance therapy for prevention and suppression of the cutaneous manifestation of ENL recurrence. THALOMID is distributed in the United States under its System f! or Thalid! omide Education and Prescribing Safety (S.T.E.P.S.) program. Internationally, THALOMID is also distributed under mandatory risk-management distribution programs. ABRAXANE (paclitaxel albumin-bound particles for injectable suspension) is a solvent-free chemotherapy treatment option for metastatic breast cancer, which was developed using its nab technology platform. This protein-bound chemotherapy agent combines paclitaxel with albumin. As of December 31, 2011, ABRAXANE was in various stages of investigation for the treatment of expanded applications for metastatic breast; non-small cell lung; malignant melanoma; pancreatic; bladder and ovarian.
ISTODAX (romidepsin) has received orphan drug designation for the treatment of non-Hodgkin's T-cell lymphomas, which includes CTCL and PTCL. The Company has licensed the worldwide rights (excluding Canada) regarding certain chirally pure forms of methylphenidate for FOCALIN and FOCALIN XR to Novartis. It also licensed to Novartis the rights related to long-acting formulations of methylphenidate and dex-methylphenidate products which are used in FOCALIN XR and RITALIN LA.
Preclinical and Clinical-Stage Pipeline
The product candidates in the Company�� pipeline are at various stages of preclinical and clinical development. Pomalidomide is a small molecule that is orally available and modulates the immune system and other biologically important targets. Pomalidomide is being evaluated in a phase III clinical trial for the treatment of myelofibrosis and a phase III clinical trial evaluating pomalidomide as a treatment for patients with relapsed/refractory multiple myeloma is accruing patients.
The Company is developing a product, ORAL ANTI-INFLAMMATORY AGENTS, which is orally available small molecules that target PDE4, an intracellular enzyme that modulates the production of multiple pro-inflammatory and anti-inflammatory mediators, including interleukin-2 (IL-2), IL-10, IL-12, IL-23, INF-gamma, TNF-a, leukotrienes,! and nitr! ic oxide synthase. Its investigational drug, apremilast (CC-10004), is used for the treatment of moderate to severe psoriasis and active psoriatic arthritis and is being evaluated in a phase II trial for rheumatoid arthritis and six phase III multi-center international clinical trials. In addition, it is investigating its oral PDE4 inhibitor, CC-11050, which is an anti-inflammatory compound that treat a variety of chronic inflammatory conditions, such as Cutaneous Lupus Erythematosus (CLE).
The Company�� oral kinase inhibitor platform includes inhibitors of the c-Jun N-terminal kinase (JNK) mTOR kinase, spleen tyrosine kinase (Syk) c-fms tyrosine kinase (c-FMS) and DNA-dependent protein kinase (DNAPK). Its oral Syk, c-FMS and DNAPK kinase inhibitors are being investigated in pre-clinical studies. The Company�� new second generation JNK inhibitor, tanzisertib (CC-930), is being evaluated in a phase II trial for the treatment of idiopathic pulmonary fibrosis and a phase II trial for the treatment of discoid lupus is accruing patients. Amrubicin is a third-generation fully synthetic anthracycline molecule with potent topoisomerase II inhibition.
At Celgene Cellular Therapeutics (CCT), it is researching stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the Company�� research and development division. Stem cell based therapies provide disease-modifying outcomes for serious diseases, which lack adequate therapy. It has developed technology for collecting, processing and storing placental stem cells with broad therapeutic applications in cancer, auto-immune diseases, including Crohn's disease, multiple sclerosis, neurological disorders, including stroke and amyotrophic lateral sclerosis (ALS), graft-versus-host disease, and other immunological / anti-inflammatory, rheumatologic and bone disorders.
The Company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept. Two phase I clinical studies have been co! mpleted. ! An additional phase II clinical study has been initiated and is ongoing related to treatments for end-stage renal anemia and to evaluate effects on red blood cell mass and plasma volume.
The Company competes with Abbott Laboratories, Amgen Inc. (Amgen), AstraZeneca PLC., Biogen Idec Inc., Bristol-Myers Squibb Co., Eisai Co., Ltd., F. Hoffmann-LaRoche Ltd., Johnson and Johnson, Merck and Co., Inc., Novartis AG, Pfizer, Sanofi and Takeda Pharmaceutical Co. Ltd. (Takeda).
Advisors' Opinion:- [By David Williamson]
In this video, David Williamson reviews some of his favorite biotech firms. Many analysts have thrown their weight behind Biogen� (NASDAQ: BIIB ) and its new BG12 drug for multiple sclerosis. However, David favors Gilead� (NASDAQ: GILD ) over Biogen since Gilead�has a�larger, more diverse product pipeline. Celgene� (NASDAQ: CELG ) is the No. 1 biotech in David's opinion since it also has blockbuster drugs but a PEG of less than 1.0. Amgen� (NASDAQ: AMGN ) is�a big company with more products in development than most people realize. Overall, for value and future earnings potential, David likes Celgene the best.
- [By Keith Speights]
Celgene (NASDAQ: CELG ) also performed well in our key metrics. The company's ROIC over the past year was 17%, but the five-year average of 4.1% dragged its overall ranking. Celgene's earnings growth of 432% over the last five years places the company high in the pecking order.�
10 Best Performing Stocks To Own For 2014: China Nepstar Chain Drugstore Ltd (NPD)
China Nepstar Chain Drugstore Ltd. operates retail drugstores in the People?s Republic of China. The company?s drugstores provide pharmacy services and other merchandise, including prescription drugs; over-the-counter drugs; nutritional supplements, such as healthcare supplements, vitamins, minerals, and dietary products; herbal products, including drinkable herbal remedies and packages of assorted herbs for making soup; and private label products. Its stores also offer personal care products, such as skin care, hair care, and beauty products; family care products, including portable medical devices for family use, birth control products, and early pregnancy test products; and convenience products, such as soft drinks, packaged snacks, other consumables, cleaning agents, and stationeries, as well as seasonal and promotional items. The company operates its stores under the China Nepstar brand name. As of December 31, 2009, its store network comprised 2,479 retail drugstores located in approximately 71 cities in Guangdong, Jiangsu, Zhejiang, Liaoning, Shandong, Hunan, Fujian, Sichuan, and Hubei provinces, as well as in Shanghai, Tianjin, and Beijing municipalities of the People?s Republic of China. The company was founded in 1995 and is headquartered in Shenzhen, the People?s Republic of China.
Advisors' Opinion:- [By Garrett Cook]
Non-cyclical consumer goods & services shares dropped around 0.20 percent in today’s trading. Top decliners in the sector included K12 (NYSE: LRN), China Nepstar Chain Drugstore (NYSE: NPD), and Du Pont (NYSE: DD).
10 Best Performing Stocks To Own For 2014: Onyx Service & Solutions Inc (ONYX)
Onyx Service & Solutions, Inc., incorporated on November 25, 2009, focuses on energy solutions. The Company is a solar products manufacturer and supplier. Utilizing Polycrystalline silicon, with 72 cells in series, it provides 240 watt, 245 watt, 250 watt, 255 watt, 260 watt, 265 watt, 270 watt, 275 watt and 280 watt configurations. Its 72 cell panel size is 1955 x 992 x 50 millimeters. It also provides panels, which utilize 54 cells in series for 200 watt, 205 watt, 210 watt and 215 watt configurations. The Company is also a provider of both privately-owned and company-owned automatic teller machines (ATM��), in Onondaga County in upstate New York. The Company receives revenues from the collection of the surcharge revenues and inter-exchange revenues. As of July 31, 2011, it owned three ATMs and manages 19 ATMS throughout upstate New York. On August 22, 2011, the Company acquired Southern Geo Power Corp. (SGPC).
The Company�� 54 cell panel size is 1482 x 992 x 50 millimeters. ONYX/Optimum Solar silicon ingots are provided in both Monocrystalline and Polycrystalline versions. Its ingots are P type with Boron dopant. ONYX/Optimum solar silicon wafers are Polycrystalline solar cell materials. Its wafers are provided in the 156 x 156 millimeter size with a thickness of 220 micrometer/ 220 micrometer +/- 40 micrometer. ONYX/Optimum Solar cells are crystalline materials. It offers two models of solar cells, its Mono five inches (R150) 125S and its Mono five inches (R165) 125SL. Its R150 125S delivers 10 different levels of efficiency and its R165 125SL delivers 11 different levels of efficiency. ONYX Solar Air Conditioning Units offer thermal solar, as well as photovoltaic alternate current (AC) technology solutions. ONYX Solar Street Lights employed for both surface road and elevated highway use, in single or multiple unit setups. Its solar street lights are replenished within the sunlit hours of the day, enabling sustained performance throughout the night.
ONYX Solar Desalin! ization Systems are driven by means of photovoltaic panels, making use of pressure pumps, which force sea water across a membrane filtration system. ONYX/Optimum Solar 300 watt grid-tied micro photovoltaic inverter model OSI-300 is designed for superior installation, functionality and field maintenance. ONYX Solar Photovoltaic (PV) Glass is able to supply power to any given location with access to sunlight. ONYX Solar Well-Water Pump Systems are available in four energy options for use in a range of functions. Its solar well water pump systems were developed for virtual maintenance-free operation, rendering these units as solution for usage throughout isolated regions, including those without an electricity infrastructure readily available. ONYX Solar�� Vertical Vane Wind Turbines thrive on their ability to deliver energy from the smallest of application sites with the most stringent requirements. Each unit is able to deliver six kilowatts of power and may be used in multi-unit configurations. Onyx Solar�� Attic Fans operate within attic room setup, delivering needed aid in overall temperature regulation of the entire home or industrial/commercial building. Each fan supplies a steady exchange rate of 1600 cubic feet per minute.
Advisors' Opinion:- [By Lee Jackson]
Amgen Inc. (NASDAQ: AMGN) is a company doing the acquiring. The company recently completed a $10.4 billion purchase of Onyx Pharmaceuticals Inc. (NASDAQ: ONYX) to add its cancer drug Kyprolis to its already sprawling portfolio. UBS has a $124 price target on the stock. The consensus target is at $123. Investors are paid a 1.7% dividend.
10 Best Performing Stocks To Own For 2014: Ventas Inc. (VTR)
Ventas, Inc. is a publicly owned real estate investment trust. The firm engages in investment, management, financing, and leasing of properties in the healthcare industry. It invests in the real estate markets of the United States and Canada. The firm primarily invests in healthcare-related facilities including hospitals, skilled nursing facilities, senior housing facilities, medical office buildings, and other healthcare related facilities. Ventas, Inc. was founded in 1983 and is based in Chicago, Illinois with additional offices in Louisville, Kentucky and Dallas, Texas.
Advisors' Opinion:- [By Justin Loiseau]
Health or wealth -- why not both?
Cliffs Natural Resources and Caterpillar shares could continue their adjustments today, but investors will also need to keep an eye on Ventas' (NYSE: VTR ) 10 a.m. EDT earnings report. The health care REIT's shares have moved from 5% gains to a 12% drop over the last three months, and year-to-date gains clock in at 6.8% so far. - [By Dividends4Life]
Ventas, Inc. (VTR) is a publicly owned real estate investment trust that engages in investment, management, financing, and leasing of properties in the healthcare industry. December 9th the company increased its quarterly dividend 8.25 to $0.725 per share. The dividend is payable December 31, 2013, to stockholders of record on December 16, 2013. The yield based on the new payout is 5.0%.
- [By Sue Chang and Ben Eisen]
Ventas Inc. (VTR) �rose 4.6%. The stock was upgraded to buy from neutral with a price target of $63 at UBS.
No comments:
Post a Comment